Is Vor Biopharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Vor Biopharma Inc (VOR) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Vor Biopharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Vor Biopharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Vor Biopharma Inc?

Muslim investors may consider investing in Vor Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Vor Biopharma Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Vor Biopharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Vor Biopharma Inc updated?

The Shariah compliance status of Vor Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Vor Biopharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Vor Biopharma Inc?

You can check the latest Shariah compliance status of Vor Biopharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

VOR Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 02, 2026

Report Source: 2025 Annual Report

Vor Biopharma Inc. Stock Analysis VOR

United States Health Care Small Cap Report: 2025 Annual

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Key Statistics of Vor Biopharma Inc (VOR)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$14.57$15.36

Today's Open

$14.89

Volume

649.91K

P/E Ratio (TTM)

52 Week Range

$3.06$65.80

Market Cap

758.11M

Avg. Volume

987.31K

Dividend Yield

Financial Metrics & Statements of Vor Biopharma Inc (VOR)

FAQ's for Vor Biopharma Inc (VOR)

According to Musaffa’s Shariah screening methodology, Vor Biopharma Inc (VOR) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.